Belatacept in Pancreas Transplantation: Promising Insights From a Cohort Series

Transpl Int. 2024 Apr 16:37:12778. doi: 10.3389/ti.2024.12778. eCollection 2024.

Authors

Christophe Masset^{1

2}, Claire Garandeau¹, Simon Ville^{1

2}, Magali Giral^{1

2}, Aurélie Houzet¹, Julien Branchereau^{1

2}, Ismaël Chelghaf¹, Benoit Mesnard^{1

2}, Gilles Blancho^{1

2}, Jacques Dantal^{1

2}, Diego Cantarovich¹

Affiliations

¹ Institut de Transplantation-Urologie-Néphrologie (ITUN), Nantes University Hospital, Nantes, France.
² Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, Unité Mixte de Recherche (UMR), Nantes, France.

No abstract available

Keywords: belatacept conversion; calcineurin inhibitor toxicity; pancreas allograft function; pancreas transplantation; rejection.

Publication types

Letter

MeSH terms

Abatacept* / therapeutic use
Adult
Cohort Studies
Female
Graft Rejection / prevention & control
Graft Survival / drug effects
Humans
Immunosuppressive Agents* / therapeutic use
Male
Middle Aged
Pancreas Transplantation*
Retrospective Studies

Substances

Abatacept
Immunosuppressive Agents

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.